Amneal's $83M Saol Acquisition Deal Expands Its Neurology Presence Into Spasticity

Amneal Pharmaceuticals Inc AMRX has agreed to acquire Saol's Baclofen franchise, including Lioresal, Lyvispah, and a pipeline product under development for $83.5 million in cash

  • The acquisition expands Amneal's commercial institutional and specialty portfolio in neurology while adding commercial infrastructure in advance of its entry into the biosimilar institutional market. 
  • The transaction is expected to be accretive to Amneal's adjusted EBITDA and adjusted EPS results for 2022.
  • Lioresal is an intrathecal baclofen product delivered through an implantable intrathecal pump to manage severe spasticity of cerebral or spinal origin for the institutional market. 
  • It has approximately $25 million in annual net revenue. 
  • Lyvispah is a baclofen oral granules specialty product recently approved by the FDA for spasticity. 
  • The product will launch in 2022. 
  • Together, Amneal expects these two products to generate between $40 and $50 million in combined annual net revenues by 2025.
  • At the end of Q3, Amneal held cash and cash equivalents of $302.6 million.
  • Price Action: AMRX shares are up 4.29% at $5.10 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasM&ANewsPenny StocksHealth CareSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!